• Standard BioTools reported first-quarter revenue of USD 21.1 million, up 5% year over year.
• Operating loss narrowed 54% to USD 12.5 million, while net loss from continuing operations improved 37% to USD 14.6 million.
• Adjusted EBITDA loss narrowed 78% to USD 3.1 million, as operating expenses fell 37% to USD 23.8 million.
• Cash and investments totaled USD 524 million at March 31, excluding a USD 25 million earnout received after quarter end; management said sale of SomaLogic to Illumina is complete and focus is shifting to strategic capital deployment.
• Standard BioTools maintained full-year revenue outlook of USD 80 million to USD 85 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605051605PRIMZONEFULLFEED9713645) on May 05, 2026, and is solely responsible for the information contained therein.